Title

Pixantrone plus rituximab versus gemcitabine plus rituximab in patients with relapsed aggressive B-cell non-Hodgkin lymphoma not eligible for stem cell transplantation: a phase 3, randomized, multicentre trial (PIX306).

Authors

Ruth Pettengell
Monika Długosz-Danecka
David Andorsky
David Belada
Pencho Georgiev
Donald Quick, Joe Arrington Cancer Research Treatment Center, Lubbock, TX, USA.Follow
Jack W Singer
Simran B Singh
Athanasios Pallis
Anton Egorov
Gilles Salles

Document Type

Article

Publication Date

1-1-2020

Publication Title

British journal of haematology

Abstract

PIX306 was a phase 3, randomised, single-blind, multicentre trial conducted in adult patients with diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma (FL) grade 3 who relapsed after ≥1 rituximab-containing regimen and were not eligible for a stem cell transplant. Patients were randomised 1:1 to pixantrone 50 mg/m

Clinical Institute

Cancer

Department

Oncology

Department

Hematology

Recommended Citation

Pettengell, Ruth; Długosz-Danecka, Monika; Andorsky, David; Belada, David; Georgiev, Pencho; Quick, Donald; Singer, Jack W; Singh, Simran B; Pallis, Athanasios; Egorov, Anton; and Salles, Gilles, "Pixantrone plus rituximab versus gemcitabine plus rituximab in patients with relapsed aggressive B-cell non-Hodgkin lymphoma not eligible for stem cell transplantation: a phase 3, randomized, multicentre trial (PIX306)." (2020). Articles, Abstracts, and Reports. 2606.
https://digitalcommons.providence.org/publications/2606